WO2008117154A3 - Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation - Google Patents

Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation Download PDF

Info

Publication number
WO2008117154A3
WO2008117154A3 PCT/IB2008/000678 IB2008000678W WO2008117154A3 WO 2008117154 A3 WO2008117154 A3 WO 2008117154A3 IB 2008000678 W IB2008000678 W IB 2008000678W WO 2008117154 A3 WO2008117154 A3 WO 2008117154A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
pharmaceutical compositions
coa reductase
reductase inhibitor
preparation
Prior art date
Application number
PCT/IB2008/000678
Other languages
English (en)
Other versions
WO2008117154A2 (fr
Inventor
Navin Ishwarlal Vaya
Monesh Pramod Dixit
Suryakant Vamanrao Navale
Original Assignee
Torrent Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Limited filed Critical Torrent Pharmaceuticals Limited
Publication of WO2008117154A2 publication Critical patent/WO2008117154A2/fr
Publication of WO2008117154A3 publication Critical patent/WO2008117154A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques stables d'inhibiteur d'HMG-CoA réductase et sur leur procédé de préparation. Plus particulièrement, elle porte sur des compositions pharmaceutiques d'inhibiteur d'HMG-CoA réductase comprenant du polyéthylène glycol (PEG), un ou plusieurs agents alcalinisants, et des excipients pharmaceutiquement acceptables; et sur un procédé pour préparer de telles compositions.
PCT/IB2008/000678 2007-03-26 2008-03-24 Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation WO2008117154A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN547/MUM/2007 2007-03-26
IN547MU2007 2007-03-26

Publications (2)

Publication Number Publication Date
WO2008117154A2 WO2008117154A2 (fr) 2008-10-02
WO2008117154A3 true WO2008117154A3 (fr) 2009-10-22

Family

ID=39789097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/000678 WO2008117154A2 (fr) 2007-03-26 2008-03-24 Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation

Country Status (1)

Country Link
WO (1) WO2008117154A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011001450A1 (fr) * 2009-06-29 2011-01-06 Alkem Laboratories Ltd. Composition pharmaceutique orale comprenant de l'atorvastatine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
WO2006037347A1 (fr) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Compositions pharmaceutiques contenant du fenofibrate et de l'atorvastatine
WO2006059224A1 (fr) * 2004-12-02 2006-06-08 Warner-Lambert Company Llc Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
WO2006084474A2 (fr) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686104A (en) * 1993-01-19 1997-11-11 Warner-Lambert Company Stable oral CI-981 formulation and process of preparing same
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
WO2006037347A1 (fr) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Compositions pharmaceutiques contenant du fenofibrate et de l'atorvastatine
WO2006059224A1 (fr) * 2004-12-02 2006-06-08 Warner-Lambert Company Llc Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
WO2006084474A2 (fr) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S Preparation pharmaceutique stable comprenant une dose fixe de fenofibrate et d'un inhibiteur de la hmg-coa reductase

Also Published As

Publication number Publication date
WO2008117154A2 (fr) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2007086078A3 (fr) Compositions pharmaceutiques atypiques et processus de preparation correspondant
WO2007100614A3 (fr) FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE
WO2008038003A3 (fr) Compositions pharmaceutiques
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
WO2007027527A3 (fr) Composes d'isoindole-imide et compositions renfermant ceux-ci et procedes d'utilisation de ceux-ci
WO2008027542A3 (fr) Composés d'isoindoline substituée en 5
WO2009066315A3 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
WO2008006795A3 (fr) Composés d'indole
UY30365A1 (es) Comprimido bicapa para la prevención de los accidentes cardiovasculares
WO2010082220A3 (fr) Composition pharmaceutique à libération prolongée à base de quétiapine et son procédé de préparation
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2007095661A8 (fr) Peptides et derives peptidiques, leur production et leur utilisation dans la preparation d'une composition pharmaceutique active therapeutiquement et/ou a titre preventif
WO2014016754A3 (fr) Compositions pharmaceutiques d'inhibiteur de la pompe à protons
WO2008101173A3 (fr) Compositions et matériaux biodégradables
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone
WO2010046932A3 (fr) Composition pharmaceutique de minocycline à libération prolongée et son procédé
WO2008020314A3 (fr) Formulations de dosage stabilisantes à base de statine
WO2009015446A3 (fr) Nouveaux inhibiteurs de réplication virale
WO2008004100A9 (fr) Composés thérapeutiques
WO2008039894A3 (fr) Compositions pharmaceutiques d'atorvastatine
WO2009048940A3 (fr) Formulations pharmaceutiques de diacéréine
WO2008117154A3 (fr) Compositions pharmaceutiques stables d'inhibiteur de hmg-coa réductase et leur procédé de préparation
WO2007110765A3 (fr) Procedes de preparation d'octreotide
WO2009016608A3 (fr) Compositions pharmaceutiques de fénofibrate
MX2009005804A (es) Composicion farmaceutica de memantina.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08762678

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08762678

Country of ref document: EP

Kind code of ref document: A2